Loading...
XTAI
4737
Market cap139mUSD
Jul 09, Last price  
57.90TWD
1D
1.58%
1Q
-13.45%
Jan 2017
3.58%
IPO
-42.68%
Name

Bionime Corp

Chart & Performance

D1W1MN
XTAI:4737 chart
P/E
P/S
2.43
EPS
Div Yield, %
3.45%
Shrs. gr., 5y
0.47%
Rev. gr., 5y
1.96%
Revenues
1.84b
-4.92%
937,752,0001,211,743,0001,476,543,0001,435,022,0001,560,897,0001,524,669,0001,609,718,0001,740,309,0001,820,267,0002,007,222,0002,172,923,0001,668,586,0001,849,924,0002,210,589,0001,755,567,0001,933,746,0001,838,588,000
Net income
-180m
L+41.71%
135,237,000136,050,000179,111,00034,147,00089,929,00054,309,00098,793,000178,790,000149,608,000128,032,000106,258,00062,434,00087,413,00091,025,0006,209,000-127,216,000-180,277,000
CFO
495m
+2,433.55%
207,558,00013,661,000216,930,00023,575,000128,981,000359,843,000200,365,000457,836,00029,599,000121,898,000405,556,000217,556,000269,722,000142,292,000203,443,00019,530,000494,802,000
Dividend
Jul 29, 20241.9984 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China, Switzerland, the United States, Algeria, and Egypt. Its primary product line features blood glucose monitoring systems, along with essential complementary items like test strips and lancing devices. These healthcare solutions are supplied to a varied customer base, including hospitals, pharmacies, and other medical equipment enterprises. Beyond its core medical device business, Bionime also engages in providing biotechnology-related services, performing pharmaceutical analysis, and marketing high-precision tools. The company was founded in 2003.
IPO date
Aug 26, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT